|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2002
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension
Institute of Cardiology, University of Bologna, Bologna, Italy
CORRESPONDENCE: N. Galiè, Istituto di Cardiologia, Università di Bologna, via Massarenti, 9, 40138-Bologna, Italy. Fax: 39 051344859. E-mail: n.galie@bo.nettuno.it
Keywords: beraprost, bosentan, endothelin, iloprost, prostacyclin, treprostinil
Received: June 27, 2002
Accepted July 1, 2002
Abstract
Past medical therapy for pulmonary arterial hypertension included the use of calcium-channel antagonists in acute vasoreactive subjects and oral anticoagulants and continuous intravenous administration of epoprostenol in the more severe cases. Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogues treprostinil, beraprost and iloprost, and the endothelin receptor antagonist bosentan have been tested in clinical trials in >1,100 patients.
Except for terbogrel, all compounds improved the mean exercise capacity by different degrees, as assessed by the 6-min walk test. In the evaluation of the clinical relevance of exercise capacity improvements, additional elements need to be considered, such as baseline functional class and concomitant favourable effects on combined clinical events (including hospitalisations, mortality and rescue therapies), quality of life and haemodynamics. No trials have shown effects on mortality, as the study protocols were not designed for assessing this end-point. Each new compound presents side-effects that are unpredictable in the individual patient and require appropriate attention upon treatment initiation and maintenance.
These new therapeutic options will be available in the near future and will allow tailoring of the most appropriate treatment to the single patient, according to an individualised benefit-to-risk ratio.
This article has been cited by other articles:
|
|
 |
|
  A. J. Peacock, R. Naeije, N. Galie, and L. Rubin End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J., July 1, 2009; 34(1): 231 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kamio, X. Liu, H. Sugiura, S. Togo, T. Kobayashi, S. Kawasaki, X. Wang, L. Mao, Y. Ahn, C. Hogaboam, et al. Prostacyclin Analogs Inhibit Fibroblast Contraction of Collagen Gels through the cAMP-PKA Pathway Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, T. Welte, G. Izbicki, D. Rosengarten, E. Picard, W. G. Kuschner, N. Galie, L. J. Rubin, and G. Simonneau Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med., March 9, 2006; 354(10): 1091 - 1093. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wahn, J. Wolf, F. Kram, S. Frantz, and J. A. Wagner The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2491 - H2496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, D. Badesch, R. Oudiz, G. Simonneau, M. D. McGoon, A. M. Keogh, A. E. Frost, D. Zwicke, R. Naeije, S. Shapiro, et al. Ambrisentan Therapy for Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., August 2, 2005; 46(3): 529 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Fike, Y. Zhang, and M. R. Kaplowitz Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets J Appl Physiol, August 1, 2005; 99(2): 670 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Harmatz, D. Ketteridge, R. Giugliani, N. Guffon, E. L. Teles, M. C. S. Miranda, Z.-F. Yu, S. J. Swiedler, J. J. Hopwood, and for the MPS VI Study Group Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase Pediatrics, June 1, 2005; 115(6): e681 - e689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert Improving survival in pulmonary arterial hypertension Eur. Respir. J., February 1, 2005; 25(2): 218 - 220. [Full Text] [PDF]
|
|
|
|
 |
|
 Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436. [Full Text] [PDF]
|
|
|
|
|
|
M.M. Hoeper and A.T. Dinh-Xuan Combination therapy for pulmonary arterial hypertension: still more questions than answers Eur. Respir. J., September 1, 2004; 24(3): 339 - 340. [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst Prostanoid therapy for pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 56S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.M. Kawut and H.I. Palevsky New answers raise new questions in pulmonary arterial hypertension Eur. Respir. J., June 1, 2004; 23(6): 799 - 801. [Full Text] [PDF]
|
|
|
|
|
|
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves End points in pulmonary arterial hypertension: the way forward Eur. Respir. J., June 1, 2004; 23(6): 947 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Humbert, O. Sitbon, and G. Simonneau Novel therapeutic perspectives in pulmonary arterial hypertension Eur. Respir. J., August 1, 2003; 22(2): 193 - 194. [Full Text] [PDF]
|
|
|
|
|
|
J.A. Barbera, V.I. Peinado, and S. Santos Pulmonary hypertension in chronic obstructive pulmonary disease Eur. Respir. J., May 1, 2003; 21(5): 892 - 905. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |